Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VB 2011

Drug Profile

VB 2011

Alternative Names: H-11; H-11 scFv; Novomab-G2 scFv; VB2-011

Latest Information Update: 12 Feb 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viventia Biotech
  • Developer University of Alabama at Birmingham
  • Class Antibody diagnostics; Antineoplastics; Immunoglobulin Fv fragments
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Diagnostic imaging enhancers; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Oct 2000 Novopharm Biotech is now called Viventia Biotech
  • 19 Sep 2000 Preclinical development for Breast cancer in Canada (IV)
  • 01 Dec 1999 A study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top